1. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956; 9:822–30.
Article
2. Herrada J, Cabanillas F, Rice L, et al. The clinical behavior of abdominal and multicentric Castleman disease. Ann Intern Med. 1998; 128:657–62.
3. Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic abdominal disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol. 1985; 3:1202–16.
4. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvi-rus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994; 266:1865–9.
5. Ishiyama T, Koike M, Nakamura S, et al. Interleukin-6 receptor abdominal in the peripheral B cells of patients with multicentric Castleman's disease. Ann Hematol. 1996; 73:179–82.
6. Pavlidis NA, Skopouli FN, Bai MC, Bourantas CL. A successfully treated case of multicentric angiofollicular hyperplasia with oral abdominal (Castleman's disease). Med Pediatr Oncol. 1990; 18:333–5.
7. Liberato NL, Bollati P, Chiofalo F, et al. Autoimmune hemolytic abdominal in multicentric Castleman's disease. Haematologica. 1996; 81:40–3.
8. Jorge R, Scott IU, Oliveira RC, et al. Ocular findings in a patient with Castleman's disease before and after treatment with immunosuppression and plasmapheresis. Ophthalmic Surg Lasers Imaging. 2010; 41:doi:. DOI:
10.3928/15428877-20100929-10.
Article
9. Venizelos I, Papathomas TG, Papathanasiou M, et al. Orbital abdominal in Castleman disease. Surv Ophthalmol. 2010; 55:247–55.
10. Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000; 95:56–61.
Article
11. Inatani M, Kashii S, Nosaka K, Arima N. Orbital pseudotumor as an initial manifestation of multicentric Castleman's disease. Jpn J Ophthalmol. 2005; 49:505–8.
Article
12. Severson GS, Harrington DS, Weisenburger DD, et al. Castleman's disease of the leptomeninges. Report of three cases. J Neurosurg. 1988; 69:283–6.
13. Tavoni A, Vitali C, Baglioni P, et al. Multicentric Castleman's abdominal in a patient with primary Sjogren's syndrome. Rheumatol Int. 1993; 12:251–3.
14. Koppens JM, Pon JA, Allen J, Sloan BH. Castleman's disease of the lacrimal gland. Clin Exp Ophthalmol. 2004; 32:108–10.
15. Park SH, Song SJ. Castleman's disease presenting with uveal abdominal syndrome. Korean J Ophthalmol. 2010; 24:182–5.
16. Kim U, Hwang JM. Optic neuropathy associated with Castleman disease. Korean J Ophthalmol. 2010; 24:256–9.
Article
17. Liu DT, Shields JA, Li C, et al. Hypertensive choroidopathy in Castleman's disease. Graefes Arch Clin Exp Ophthalmol. 2011; 249:1901–3.
Article
18. Oshitari T, Kajita F, Tobe A, et al. Refractory uveitis in patient with castleman disease successfully treated with tocilizumab. Case Rep Ophthalmol Med. 2012; 2012:968180.
Article
19. Kozak I, Reid EG. Retinal vein occlusion during flare of abdominal Castleman's disease. Clin Ophthalmol. 2013; 7:1647–9.
20. Katz MS, Park S, Gritz DC. Posterior segment involvement in Castleman disease. Retin Cases Brief Rep. 2014; 8:209–11.
Article
21. Lin P, Bhullar SS, Tessler HH, Goldstein DA. Immunologic abdominal as potential predictors of systemic autoimmune disease in abdominals with idiopathic scleritis. Am J Ophthalmol. 2008; 145:463–71.
22. Jabs DA, Mudun A, Dunn JP, Marsh MJ. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol. 2000; 130:469–76.
Article
23. Murphy CC, Ayliffe WH, Booth A, et al. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004; 111:352–6.